Please ensure Javascript is enabled for purposes of website accessibility

FDA Approves Neurocrine Biosciences' Parkinson's Drug

By Jim Crumly - Updated Jun 24, 2020 at 3:05PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's second commercial drug will launch later this year.

Neurocrine Biosciences (NBIX 1.82%) announced Monday that the Food and Drug Administration (FDA) has approved Ongentys (opicapone), a daily pill for Parkinson's disease.

Ongentys is an add-on treatment for Parkinson's patients who are currently taking the main first-line treatment, levodopa (L-Dopa), combined with carbidopa to moderate side effects. As the disease progresses, some patients experience more frequent episodes of  motor-function issues between their levodopa treatments. Ongentys is a COMT inhibitor, a drug that blocks the enzyme that breaks down levodopa, therefore prolonging its clinical effects during those "off times."

Pill and a pill bottle.

Image source: Getty Images.

There are currently about 1 million Parkinson's patients in the U.S., with about 70% of them taking levodopa; among that group, 70% take some sort of add-on treatment. Neurocrine's aspiration for Ongentys is for it to become a standard add-on treatment for Parkinson's sufferers when levodopa is no longer adequately controlling their symptoms. The drug was approved in Europe in 2016, and Neurocrine obtained exclusive development and commercialization rights for it in the U.S. and Canada in 2017.

Earlier this month the company said it would delay its commercial launch of Ongentys in the U.S. and Canada until later this year due to the COVID-19 pandemic, which left it unsure about to its ability to get an adequate supply of the drug. Ongentys is Neurocrine's second commercial drug, joining Ingrezza, which helped the biotech deliver 75% revenue growth in 2019, and sent the stock upward by more than 50%.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Neurocrine Biosciences, Inc. Stock Quote
Neurocrine Biosciences, Inc.
NBIX
$99.25 (1.82%) $1.77

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.